Relationship between homocysteine level and diabetic retinopathy: a systematic review and meta-analysis

Diagnostic Pathology

Jing Yu²  Fang Wang²  Xiaoqiang Liu²  Guodong Liu²  Yan Wu¹  Chong Xu² 

[1]Department of First Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu, China

[2]Department of Ophthalmology, Shanghai Tenth People¿s Hospital, Affiliate of Tongji University School of Medicine, Shanghai 200072, China

关键词: Diabetic retinopathy (DR);    Homocysteine;    Hyperhomocysteinemia;   

Others  :  1149759
DOI  :  10.1186/s13000-014-0167-y

 received in 2014-06-26, accepted in 2014-08-16,  发布年份 2014

【 摘 要 】

Background

The relationship between homocysteine (Hcy) and diabetic retinopathy (DR) remains unclear to date. Therefore, a systematic review and meta-analysis was performed on the relationship between Hcy level and DR.

Methods

Studies were identified by searching PubMed, Embase, and Web of Science databases until 5 May, 2014.

Results

A total of 31 studies involving 6,394 participants were included in the meta-analysis. After pooling the data from each included study, the blood Hcy concentration in the DR group was observed to be higher than that in the control group [WMD?=?2.55; 95% confidence interval (CI), 1.70¿3.40], and diabetes mellitus (DM) patients with hyperhomocysteinemia were at a risk for DR [odds ratio (OR)?=?1.93; 95% CI, 1.46¿2.53]. Considering the different DM types, hyperhomocysteinemia in T1DM (OR?=?1.83, 95% CI, 1.28¿2.62) was associated with DR rather than in T2DM (OR?=?1.59, 95% CI, 0.72¿3.51). Considerable statistical heterogeneity in the overall summary estimates was partly explained by the geographical differences.

Conclusions

Results from this current meta-analysis indicate that hyperhomocysteinemia is a risk factor for DR, especially proliferative DR. Differences between geographical regions were observed in the relationship between hyperhomocysteinemia with T1DM risk. Given the heterogeneous results, the relationship between high Hcy and DR needs further investigation.

Virtual Slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_167 webcite

【 授权许可】

   
2014 Xu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Congdon NG, Friedman DS, Lietman T: Important causes of visual impairment in the world today. JAMA 2003, 290:2057-2060.
• [2]Chico A, Perez A, Cordoba A, Arcelus R, Carreras G, de Leiva A, Gonzalez-Sastre F, Blanco-Vaca F: Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia 1998, 41:684-693.
• [3]Agullo-Ortuno MT, Albaladejo MD, Parra S, Rodriguez-Manotas M, Fenollar M, Ruiz-Espejo F, Tebar J, Martinez P: Plasmatic homocysteine concentration and its relationship with complications associated to diabetes mellitus. Clin Chim Acta 2002, 326:105-112.
• [4]Goldstein M, Leibovitch I, Yeffimov I, Gavendo S, Sela BA, Loewenstein A: Hyperhomocysteinemia in patients with diabetes mellitus with and without diabetic retinopathy. Eye (Lond) 2004, 18:460-465.
• [5]Hoogeveen EK, Kostense PJ, Eysink PE, Polak BC, Beks PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD: Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: the Hoorn study. Arch Intern Med 2000, 160:2984-2990.
• [6]Huang EJ, Kuo WW, Chen YJ, Chen TH, Chang MH, Lu MC, Tzang BS, Hsu HH, Huang CY, Lee SD: Homocysteine and other biochemical parameters in type 2 diabetes mellitus with different diabetic duration or diabetic retinopathy. Clin Chim Acta 2006, 366:293-298.
• [7]Brazionis L, Rowley K Sr, Itsiopoulos C, Harper CA, O¿Dea K: Homocysteine and diabetic retinopathy. Diabetes Care 2008, 31:50-56.
• [8]Vaccaro O, Ingrosso D, Rivellese A, Greco G, Riccardi G: Moderate hyperhomocysteinaemia and retinopathy in insulin-dependent diabetes. Lancet 1997, 349:1102-1103.
• [9]Vaccaro O, Perna AF, Mancini FP, Cuomo V, Sacco M, Tufano A, Rivellese AA, Ingrosso D, Riccardi G: Plasma homocysteine and its determinants in diabetic retinopathy. Diabetes Care 2000, 23:1026-1027.
• [10]Agardh E, Hultberg B, Agardh CD: Severe retinopathy in type 1 diabetic patients is not related to the level of plasma homocysteine. Scand J Clin Lab Invest 2000, 60:169-174.
• [11]Saeed BO, Nixon SJ, White AJ, Summerfield GP, Skillen AW, Weaver JU: Fasting homocysteine levels in adults with type 1 diabetes and retinopathy. Clin Chim Acta 2004, 341:27-32.
• [12]Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
• [13]Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010, 25:603-605.
• [14]Gagne JJ, Power MC: Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010, 74:995-1002.
• [15]Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
• [16]Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
• [17]Golbahar J, Rahimi M, Tabei MB, Aminzadeh MA: Clinical risk factors and association of hyperhomocysteinemia with diabetic retinopathy in Iranian type 2 diabetes patients: a cross-sectional study from Shiraz, Southern Iran. Diabetes Metab Syndr Clin Res Rev 2008, 2:192-201.
• [18]Hofmann MA, Kohl B, Zumbach MS, Borcea V, Bierhaus A, Henkels M, Amiral J, Schmidt AM, Fiehn W, Ziegler R, Wahl P, Nawroth PP: Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1998, 21:841-848.
• [19]Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP: Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 2000, 23:1816-1822.
• [20]de Luis DA, Fernandez N, Arranz ML, Aller R, Izaola O, Romero E: Total homocysteine levels relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of patients with diabetes mellitus type 2. J Diabetes Complications 2005, 19:42-46.
• [21]Satyanarayana A, Balakrishna N, Pitla S, Reddy PY, Mudili S, Lopamudra P, Suryanarayana P, Viswanath K, Ayyagari R, Reddy GB: Status of B-vitamins and homocysteine in diabetic retinopathy: association with vitamin-B12 deficiency and hyperhomocysteinemia. PLoS One 2011, 6:e26747.
• [22]Chen YS: Contents changes and correlations between Hcy and Cystatin C in patients with diabetic retinopathy in type 2 diabetes mellitus. Int J Ophthal 2010, 10:2107-2110.
• [23]Lim CP, Loo AV, Khaw KW, Sthaneshwar P, Khang TF, Hassan M, Subrayan V: Plasma, aqueous and vitreous homocysteine levels in proliferative diabetic retinopathy. Br J Ophthalmol 2012, 96:704-707.
• [24]Hultberg B, Agardh E, Andersson A, Brattstrom L, Isaksson A, Israelsson B, Agardh CD: Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 1991, 51:277-282.
• [25]Smulders YM, Rakic M, Slaats EH, Treskes M, Sijbrands EJ, Odekerken DA, Stehouwer CD, Silberbusch J: Fasting and post-methionine homocysteine levels in NIDDM: determinants and correlations with retinopathy, albuminuria, and cardiovascular disease. Diabetes Care 1999, 22:125-132.
• [26]Stabler SP, Estacio R, Jeffers BW, Cohen JA, Allen RH, Schrier RW: Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus. Metabolism 1999, 48:1096-1101.
• [27]Chiarelli F, Pomilio M, Mohn A, Tumini S, Vanelli M, Morgese G, Spagnoli A, Verrotti A: Homocysteine levels during fasting and after methionine loading in adolescents with diabetic retinopathy and nephropathy. J Pediatr 2000, 137:386-392.
• [28]Buysschaert M, Jamart J, Dramais AS, Wallemacq P, Hermans MP: Micro- and macrovascular complications and hyperhomocysteinaemia in type 1 diabetic patients. Diabetes Metab 2001, 27:655-659.
• [29]Yang G, Lu J, Pan C: The impact of plasma homocysteine level on development of retinopathy in type 2 diabetes mellitus. Zhonghua Nei Ke Za Zhi 2002, 41:34-38.
• [30]Abdella NA, Mojiminiyi OA, Akanji AO, Moussa MA: Associations of plasma homocysteine concentration in subjects with type 2 diabetes mellitus. Acta Diabetol 2002, 39:183-190.
• [31]Looker HC, Fagot-Campagna A, Gunter EW, Pfeiffer CM, Narayan KM, Knowler WC, Hanson RL: Homocysteine as a risk factor for nephropathy and retinopathy in type 2 diabetes. Diabetologia 2003, 46:766-772.
• [32]Garcia-Unzueta MT, Berrazueta JR, Pesquera C, Obaya S, Fernandez MD, Sedano C, Amado JA: Levels of plasma total adrenomedullin are related with two acute phase inflammatory reactants (fibrinogen and sialic acid) but not with markers of endothelial dysfunction in type 1 diabetes adrenomedullin and vascular risk factors in type 1 DM. J Diabetes Complications 2005, 19:147-154.
• [33]Yücel I, Yücel G, Müftüoglu F: Plasma homocysteine levels in noninsulin-dependent diabetes mellitus with retinopathy and neovascular glaucoma. Int Ophthalmol 2004, 25(4):201-205.
• [34]Aydin E, Demir HD, Ozyurt H, Etikan I: Association of plasma homocysteine and macular edema in type 2 diabetes mellitus. Eur J Ophthalmol 2008, 18:226-232.
• [35]Aydemir O, Turkcuoglu P, Guler M, Celiker U, Ustundag B, Yilmaz T, Metin K: Plasma and vitreous homocysteine concentrations in patients with proliferative diabetic retinopathy. Retina 2008, 28:741-743.
• [36]Nguyen TT, Alibrahim E, Islam FM, Klein R, Klein BE, Cotch MF, Shea S, Wong TY: Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. Diabetes Care 2009, 32:1704-1709.
• [37]Cho HC: The relationship among homocysteine, bilirubin, and diabetic retinopathy. Diabetes Metab J 2011, 35:595-601.
• [38]Vaccaro O, Perna AF, Mancini FP, Iovine C, Cuomo V, Sacco M, Tufano A, Rivellese AA, Ingrosso D, Riccardi G: Plasma homocysteine and microvascular complications in type 1 diabetes. Nutr Metab Cardiovasc Dis 2000, 10:297-304.
• [39]Agardh CD, Agardh E, Andersson A, Hultberg B: Lack of association between plasma homocysteine levels and microangiopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 1994, 54:637-641.
• [40]Cronin CC, McPartlin JM, Barry DG, Ferriss JB, Scott JM, Weir DG: Plasma homocysteine concentrations in patients with type 1 diabetes. Diabetes Care 1998, 21:1843-1847.
• [41]Socha MW, Polakowska MJ, Socha-Urbanek K, Fiedor P: Hyperhomocysteinemia as a risk factor for cardiovascular diseases: the association of hyperhomocysteinemia with diabetes mellitus and renal transplant recipients. Ann Transplant 1999, 4:11-19.
• [42]Sindrey M, Marshall TL, Naish P: Quantitative assessment of the effects of platelet depletion in the autologous phase of nephrotoxic serum nephritis. Clin Exp Immunol 1979, 36:90-96.
• [43]Starkebaum G, Harlan JM: Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986, 77:1370-1376.
• [44]Chen C, Conklin BS, Ren Z, Zhong DS: Homocysteine decreases endothelium-dependent vasorelaxation in porcine arteries. J Surg Res 2002, 102:22-30.
• [45]Blacker HR: Talking to patients. Nurs Times 1976, 72:1212-1214.
• [46]Hofmann MA, Kohl B, Zumbach MS, Borcea V, Bierhaus A, Henkels M, Amiral J, Fiehn W, Ziegler R, Wahl P, Nawroth PP: Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1997, 20:1880-1886.
• [47]Russo GT, Di Benedetto A, Magazzu D, Giandalia A, Giorda CB, Ientile R, Previti M, Di Cesare E, Cucinotta D: Mild hyperhomocysteinemia, C677T polymorphism on methylenetetrahydrofolate reductase gene and the risk of macroangiopathy in type 2 diabetes: a prospective study. Acta Diabetol 2011, 48:95-101.
• [48]Coral K, Angayarkanni N, Gomathy N, Bharathselvi M, Pukhraj R, Rupak R: Homocysteine levels in the vitreous of proliferative diabetic retinopathy and rhegmatogenous retinal detachment: its modulating role on lysyl oxidase. Invest Ophthalmol Vis Sci 2009, 50:3607-3612.
• [49]Zhao C, Wang W, Xu D, Li H, Li M, Wang F: Insulin and risk of diabetic retinopathy in patients with type 2 diabetes mellitus: data from a meta-analysis of seven cohort studies. Diagn Pathol 2014, 9:130. BioMed Central Full Text
• [50]Tang L, Ye H, Hong Q, Chen F, Wang Q, Xu L, Bu S, Liu Q, Ye M, Wang DW, Mai Y, Duan S: Meta-analyses between 18 candidate genetic markers and overweight/obesity. Diagn Pathol 2014, 9:56. BioMed Central Full Text
• [51]Ganapathy PS, White RE, Ha Y: The role of N-methyl-D-aspartate receptor activation in homocysteine-induced death of retinal ganglion cells. Invest Ophthalmol Vis Sci 2011, 52:5515-5524.
• [52]Wang L, Teng Z, Cai S, Wang D, Zhao X, Yu K: The association between the PPARgamma2 Pro12Ala polymorphism and nephropathy susceptibility in type 2 diabetes: a meta-analysis based on 9,176 subjects. Diagn Pathol 2013, 8:118. BioMed Central Full Text
• [53]Zappacosta B, Graziano M, Persichilli S, Di Castelnuovo A, Mastroiacovo P, Iacoviello L: 5,10-Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms: genotype frequency and association with homocysteine and folate levels in middle-southern Italian adults. Cell Biochem Funct 2014, 32:1-4.
• [54]Chmurzynska A, Malinowska AM, Twardowska-Rajewska J, Gawecki J: Elderly women: homocysteine reduction by short-term folic acid supplementation resulting in increased glucose concentrations and affecting lipid metabolism (C677T MTHFR polymorphism). Nutrition 2013, 29:841-844.